• A L Melikyan, I N Subortseva, E A Gilyazitdinova, T I Koloshejnova, K S Shashkina, E K Egorova, A M Kovrigina, A B Sudarikov, and L A Gorgidze.
• National Research Center for Hematology.
• Terapevt Arkh. 2021 Jul 23; 93 (7): 800-804.

AbstractThrombotic complications are the most significant factors determining the prognosis in myeloproliferative neoplasms. Markers for assessing the risk of thrombosis are the number of leukocytes, platelets, hemoglobin level, hematocrit, age, molecular status, history of thrombosis, obesity, arterial hypertension, hyperlipidemia, hereditary or acquired thrombophilia. The pathogenesis of thrombosis in patients with myeloproliferative neoplasms is complex and multifactorial. In most cases, the etiological factor remains unknown. Currently, antiplatelet and anticoagulant therapy is carried out on an individual basis. The algorithm for primary and secondary (after thrombosis) prevention requires development and testing. We present a clinical case of repeated arterial and venous thrombotic complications in a patient with primary myelofibrosis.

15 keywords...

hide…